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1. Introduction 
Bronchopulmonary dysplasia (BPD) continues to be the most common and most important 
complication in preterm infants with RDS. The incidence varies from 20 to 60 % in preterm 
infants whose weight are < 1500 gram. The presence of BPD is often associated with 
significant mortality and short term and long term morbidity, including growth failure and 
neurodevelopment delay. 
The exact mechanism and pathogenesis of BPD is not completely understood. However, 
epidemiology study suggests a changing prevalence and clinical features in recent years. 
The traditional descriptions of BPD (so call classic or old BPD) are essentially related to lung 
injuries following mechanical ventilation while the recent description of BPD (new BPD) is 
probably related more to prematurity of the lungs. The relation between these two types of 
BPD is not clear. Recent studies indicated that inflammation may play an important role for 
both the classic and new BPD. Once lung injuries have established, managements are 
essentially supportive, therefore every effort should be focus on prevention. Proper 
respiratory care is the most essential in preventing lung injury. Other medications, either to 
improve the pulmonary function or to reduce the lung inflammation, have been tried with 
various successes. There is no magic bullet to cure the disease.  
2. Definition  
The original definition of bronchopulmonary dysplasia by Northway was base on 
radiological and pathological characteristics in prematurely born infants with respiratory 
distress syndrome (RDS) who were treated with mechanical ventilation and oxygen 
supplementation. Subsequently, the definition of BPD was changed to respiratory sequelae 
in infants requiring oxygen supplementation more than 28 days after birth since BPD may 
occur in tiny premature infants who have not previously had RDS. This definition was not 
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without debate, because it includes a wide range of infants, i.e. from those ultimately appear 
to have no residual problems to those with severe BPD. A more practical definition was 
used: respiratory sequelae in infants who reach term age but are oxygen or mechanical 
ventilation dependent. The introduction of antenatal steroid prophylaxis, postnatal 
surfactant treatment caused revolutionary care of premature infants. Nowadays, more 
extreme low birth weight infants with birth weight < 1000gm and gestation age 23-28 weeks 
survived, they experienced a mild initial respiratory course, but required a low 
concentration of oxygen for a long time. In 2001, the United States National Institute of 
Child Health and Human Development (NICHD) conducted a workshop. A new definition, 
which categorizes the severity of BPD, was proposed. 
2.1 Classic bronchopulmonary dysplasia ( Classic BPD ) 
As described above, the classic BPD was defined as a chronic lung disease occurs in 
premature infants who had respiratory distress after birth, require oxygen supplementation 
or mechanical ventilator support at 28 postnatal days or 36 weeks postmenstrual age (PMA). 
Four stages I, II, III and IV are classified base on radiological findings and associated 
pathologic changes. Stage I and II describe acute and subacute course of respiratory distress 
syndrome. Stage III and IV often represent changes associated with chronic lung disease. 
Stage I  (2-3 days) is a period of acute RDS. The radiologic picture is similar to RDS. 
Stage II (4-10 days) is a period of regeneration. The chest radiograph shows complete  
 opacity of the lung obscuring the heart and lung borders. 
Stage III (10-20 days) is a period of transition to chronic disease. The early radiographic changes  
 are replaced by areas of coarse, irregular shaped densities and areas of cyst lesions.  
 Areas of density are caused by interstitial edema or atelectasis due to obstruction of  
 small bronchioles with luminal debris. The cysts represent foci of emphysema. 
Stage IV (beyond 1 month) is a period of chronic disease. Chest radiograph shows large cysts  
 and marked fibrosis and edema with areas of consolidation and areas of 
 overinflation. 
This definition becomes less relevant in current practice, since the improvement care of RDS, 
and survival of very tiny babies, classic BPD is uncommonly seen now, instead a new form 
of BPD (new BPD) is much increased. 
2.2 New bronchopulmonary dysplasia ( New BPD ) 
BPD is now defined clinically as a chronic lung disease occurring in premature infants who 
need for supplemental O2 for at least 28 days after birth, and its severity is graded according 
to the oxygen concentration and positive pressure of respiratory support at near term. For 
gestation age 32 weeks or more, the time of determination varies between 28 days to 56 days 
before discharge. For gestation age less than 32 week, the time of determination is 36 weeks 
postmenstrual age 36 weeks. A physiologic test such as pulse oximetry saturation is 
recommended to confirm the requirement of oxygen supplementation at the time of 
assessment (Table 1). Again, this definition is made clinically and the incidence of BPD can 
be various from hospital to hospital. 
3. Epidemiology 
The incidence of BPD varies among different institutions. This is due to differences in 
neonatal risk factors among different populations, patient care management and the 
discrepancies in the definition of BPD. Incidence figures must be interpreted with caution.  
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Gestation age < 32 weeks > 32 weeks 
Time point of 
assessment 
36 wk PMA or discharge to home, 
whichever comes first 
28 d to 56 d postnatal age or 
discharge to home, whichever 
comes first 
  Treatment with oxygen > 21% for at least 28 d plus 
Mild BPD Breathing room air at 36 wk PMA 
or discharge, whichever comes first  
Breathing room air by 56 d 
postnatal age or discharge, 
whichever comes first 
Moderate BPD Need for <30% oxygen at 36 PMA 
or discharge, whichever comes first 
Need for < 30% oxygen at 56 d 
postnatal age or discharge, 
whichever comes first 
Severe BPD Need for > 30% oxygen and/or 
positive pressure (PPV or NCPAP) 
at 36 wk PMA or discharge,  
whichever comes first   
Need for > 30% oxygen and/or 
positive pressure (PPV or NCPAP) 
at 56 d   postnatal age or discharge,  
whichever comes first 
Adapt from Jobe A. Bancalarie E. Bronchopulmonary Dysplasia. Am J Respir Crit Care Med 2001; 163: 
1723-1729. 
Table 1. Definition of New Bronchopulmonary Dysplasia: Diagnostic Criteria 
For example, better prenatal and postnatal care increase survival of the very tiny infants, 
more infants who previously would have died now survive and remain oxygen/ventilator 
dependent at 28 days of age, the overall rate of BPD may increase, but the severity is much 
less. The denominator may also be different, some reports used all live births of premature 
infants as denominator; while others used only survived infants. 
Parker et al reported the incidence of BPD increased from 10.6% in 1976 through 1980, to 
21.7% (981 through 1985), and to 32.9% (1986 through 1990) in very low birth weight 
neonates (1500 g or less) admitted to a regional newborn care center in USA, while there was 
concurrent decline of neonatal death during the same periods (26.4%, 18.3%, and 15.9%, 
respectively). The diagnosis of BPD was given if neonates were treated supplemental 
oxygen for at least 28 days as a surrogate for oxygen treatment on postnatal day 28. 
In 2007, a report from NICHD Neonatal Research Network database of USA shows the 
survival rate and the incidence of BPD (defined by supplemental O2 at 36 weeks PMA) in 
infants with birth weight of 501-1500g almost unchanged between1997and 2002. The 
survival increases slightly (from 84 to 85%) and the incidence of BPD decreases by 1% (from 
23 to 22%). Tiny infants have highest rate and severity of BPD: 6% in 1250-1500g; 14%in 
1001-1240g; 33% in750-1000g and 46% in 501 to 750g. 
Since the release of a consensus statement by the American Academy of Pediatrics and the 
Canadian Pediatric Society in 2002, the use of postnatal corticosteroid has decreased. There 
was concern that the decreased use of postnatal steroid might increase the risk of BPD. A 
recent report from America which includes 77520 premature infants born at <32 weeks 
gestation in California, the overall rate of BPD increased over the decade: 20% in 1997-1999, 
24% in 2000-2003 and 25.4% in 2004-2006. The rate of severe BPD also increased 
significantly: 3.6% 1997-1999, 5.1% in 2000-2003, and 9.5% in 2004-2006.  
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4. Pathology of bronchopumonary dysplasia 
The characteristic changes of classic BPD are airway injury and inflammation, airway 
epithelial cell metaplasia, and parenchymal fibrosis. In contrast, the characteristic 
morphology of “new” BPD is disruption of lung development (Figure 1).  
4.1 Classic bronchopumonary dysplasia 
Four stages are classified according to the severity and anatomic component involved.  
Stage I alveolar and interstitial edema with hyaline membranes, atelectasis, and necrosis of  
bronchial mucosa are present.  
Stage II atelectasis becomes more evident, alternating with areas of emphysema. There is 
 widespread necrosis and repair of bronchial mucosa. Cellular debris fills the 
 airways. 
Stage III extensive bronchial and bronchiolar metaplasia and hyperplasia evolve. Areas of  
 emphysema are surrounded by areas of atelectasis, accompanied by massive 
 interstitial edema with thickening of the basement membranes. 
Stage IV massive fibrosis of the lung with destruction of alveoli and airways are present. In 
 addition, there is hypertrophy of bronchial smooth muscle and metaplasia of 
 airway mucosa. Finally, there is actual loss of pulmonary arterioles and capillaries 
 and medial muscular hypertrophy of remaining vessels. 
 
 
 
Fig. 1. Airway and Parenchymal Damage in Old and New BPD. „Old“ and „new“ BPD are 
two different morphologic outcomes of variable combinations of factors capable of injuring 
lungs of differing maturity. In old BPD, intense inflammation and disruption of normal 
pulmonary structures lead to a nonhomogeneous airway and parenchymal disease. In 
contrast, the main feature of new BDP is diffusely reduced alveolar development, which is 
associated with a clinically significant loss of surface area for gas excange, with airway 
injury, inflammation, and fibrosis that are usually milder than in old BPD.  
(From Baraldi E., Filippone M. Chronic Lung Disease after Premature Birth. N Engl J M. 
2007, 357(8);1951) 
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4.2 New bronchopulmonary dysplasia 
Hislop et al. reported that mechanical ventilation of low birth weight infants leads to fewer 
alveoli. Husain et al. reported that extremely premature infants (gestation age ranged 24 to 
32 weeks) dying of BPD had partial to complete arrest in acinar development whether 
infants received surfactant treatment or not. The alveolar structures are larger, simplified, 
and fewer in numbers. The amount of alveolar septal fibrosis is substantially less and tends 
to be more diffuse in surfactant-treated infants than in infants who did not have surfactant 
treatment. Coalson studied the autopsy lung specimens from infants who had received both 
prenatal steroids and surfactant treatment and have found the following findings: enlarged 
air spaces with minimal alveolization, dysmorphic capillary configuration and variable 
alveolar wall cellularity and fibrosis. Airway and vascular lesions, when present, tend to be 
present in infants, who over time develop more severe disease. 
5. Pathogenesis 
The pathogenesis of BPD is multifactorial. The original concepts of risk factors include: (1) 
prematurity; (2) respiratory distress; (3) mechanical ventilation; (4) oxygen supplementation. 
These factors still play an important role in the development of new BPD. However, 
infection and inflammation, pulmonary edema as result of and patent ductus arteriosus 
(PDA) or fluid overloading, nutritional deficiencies and genetic factors may also contribute 
to lung injury. Classic BPD is heavily influenced by injury inflammation and fibrosis; while 
new primarily is an arrest of development, disorder or delayed modeling and remodeling. ( 
Figure 2 ) 
5.1 Prematurity 
Bronchopulmonary dysplasia occurs most commonly in premature infants. Extreme low 
birth weight infants have a deficiency of surfactant and immature lung parenchyma, 
compliant chest wall , inadequate respiratory drive and immature antioxidant enzyme 
system. Most of these infants need supplemental oxygen and assisted ventilation after birth 
to achieve adequate gas exchange. The functional and structural immaturity increases the 
risk of lung injury and disruption of normal alveolar development from antenatal and 
postnatal insults.  
Infants born at 23-28 weeks gestation are just beginning to alveolarize the distal saccule of 
the lung in parallel with the development of the alveolar capillary bed. Alveolar 
development can be delayed with hypoxia, hyperoxia, inflammations, glucocorticoids, and 
poor nutrition. 
Patent ductus arteriosus (PDA) is present in most ELBW infants. PDA shunt increases 
pulmonary blood flow, and may result in pulmonary edema. Lung compliance is reduced 
and lung resistance is increased, creating a need for more vigorous and protracted ventilator 
support. 
5.2 Oxygen toxicity  
Inspiration of high oxygen concentration is a major factor in the pathogenesis of BPD, 
though the precise concentration and duration of oxygen that is toxic to the immature lung 
has not been established. Any concentration in excess of room air might increase the risk of 
lung damage when administered over a period of time. Early pulmonary change caused by 
oxygen toxicity consists of atelectasis, edema, alveolar hemorrhage, inflammation, fibrin 
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deposition, and thickening of alveolar membrane. Continuous high oxygen exposure causes 
influx of polymorphonuclear leukocytes containing proteolytic enzymes which causes 
inflammatory reaction and cytotoxic damage. 
  
Before Birth During 
Resuscitation 
During NICU 
stay 
    Infection 
Chorioamionitis 
Mechanical ventilation 
Oxidative stress 
Mechanical ventilation 
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Vascularization 
Remodeling  
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New BPD Old BPD  
Fig. 2. Pathogenesis of Bronchopulmonary Dysplasia 
The fetal lung is exposed to relatively low oxygen tension around 20 to 30 mmHg. 
Immediately after birth, the arterial oxygen tension climbs to 100 mmHg. The sudden 
increase of oxygen tension cause substantial oxidative stress. The principle mechanism 
involves the univalent reduction of molecular oxygen and formation of free oxygen radicals 
such as superoxide free radical (O2-), hydrogen peroxide (H2O2), hydroxyl free radical (OH) 
and singlet oxygen (1O2). These oxygen free radicals are highly reactive molecules that can 
cause oxidative damage to lung tissue and trigger the inflammatory reaction. Premature 
infants have inadequate antioxidant defense system because their antioxidant enzymes such 
as superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GP) are not mature 
and nutrients deficiencies (vitamin E, vitamin C, beta-carotene, uric acid) are common, thus 
they are vulnerable to develop lung injury from oxygen toxicity.  
5.3 Mechanical ventilation-barotrauma and volutrauma 
Barotrauma is the lung injury caused by the pressure used to inflate the lung. The 
inspiratory pressures needed to inflate the surfactant-deficiency premature lungs often 
fivefold greater than the physiologic pressure of the normal lung. The alveoli are not 
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homogenous inflated; some units remain collapsed and require higher pressure to reopen, 
whereas others become over distended. The resistance of collapsed alveoli to inflate leads to 
over distension of distal bronchioles during peak inflation and damage of bronchiolar 
epithelium. These over distension of airways and irregular aeration of alveoli lead to 
inflammation and release of cytokine.  
Barotrauma produces alveolar shear stress, disruption of alveolarization, pulmonary air 
leak, and release of damaging cytokine and other biologically substances. High ventilator 
pressure has long been considered as a major cause of BPD, but tissue damage is now more 
attributed to over-distension of the lung from high tidal volume ventilation (volutrauma). In 
an animal experiment, Dreyfuss et al. demonstrated the most severe lung injury was seen 
with high tidal volume with high or low pressure. There were no abnormalities with low 
volume at high pressure. In clinical settings, however, high pressure usually delivers high 
volume, which in turn stretches alveolar wall and capillaries. 
5.4 Inflammation  
Inflammation plays the central role in the development of BPD. Inflammatory reaction may 
be triggered by factors including infection before or after birth, oxygen free radicals, 
barotraumas or volutrauma from mechanical ventilation, and pulmonary edema. 
Neutrophils and macrophages are recruited in the airway and pulmonary tissues. The 
activated neutrophils adhere to the endothelium of the pulmonary vascular system and thus 
initiate a sequence of pathogenetic events. Infants who subsequently develop BPD are found 
to have high concentration of proinflammatory and chemotactic factors in the 
tracheobronchial aspirate such as leukotrine B4, interleuleukin-1┚, interleukin-8, soluble 
ICAM-1, anaphylatoxin C5a, platelet aggregation factor and prostaglandin. Pulmonary 
inflammation affects normal alveolization and angiogenesis, these may further lead to 
remodeling of developing lung resulting in BPD. Leukotrienes may remain elevated in BPD 
infants even at 6 months of age and cause bronchoconstrictoin, vasoconstriction, edema, 
neutrophils chemotaxis and mucus production. 
5.5 Prenatal and postnatal infection 
5.5.1 Chorioamnionitis 
Premature infants who were exposed to maternal chorioamnionitis and required mechanical 
ventilation after birth have higher incidence of BPD. Proinflammatory mediators IL-1, IL-6 
and IL-8 were detected in the early tracheal aspirates from these infants, suggesting lung 
inflammation occurred before birth. Ureaplasma urealyticum is the most common organism 
associated with chorioamnionitis. Several studies have suggested an association between 
Ureaplasma urealyticum tracheal colonization and the development of severe respiratory 
failure and BPD in very low birth weight infants, but results have not been consistent.  
5.5.2 Postnatal infection  
Very low birth weight infants with early onset systemic infection or local pneumonia 
usually present with respiratory signs including cyanosis and apnea which required oxygen 
therapy or ventilator support. Intubated infants are prone to develop nosocomial infection 
with deteriorating gas exchange, and are at great risk for development of BPD. The presence 
of a systemic infection in premature infants was noted to increase the risk of late ductal 
reopening and failure to respond to medical treatment with indomethacin. Infants with 
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infection and those with PDA had higher levels of 6-ketoprostaglandin F1-┙ than did control 
subjects. Levels of tumor necrosis factor-┙ were also elevated in infants with infection and in 
those with late PDA. The risk of BPD is enhanced if there is active PDA present at the time 
of infection.  
5.6 Pulmonary edema, patent ductus arteriosus and fluid overloading 
Increases pulmonary blood flow from left-to-right shunt blood flow crossing patent ductus 
arteriosus may result increasing interstitial fluid and pulmonary edema. Pulmonary 
compliance is reduced and resistance is increased, creating a need for prolonged ventilator 
support with higher oxygen concentration and ventilation pressure. Clinical evidence 
suggests that infants with RDS who receive great fluid intake or who do not show a diuretic 
phase during the first few days of life have a high incidence of BPD. This may be because 
high fluid intake increases the incidence of PDA. Elevated concentration of myeloperoxidase 
was noted in the tracheal fluid of infants with PDA, suggesting the increased pulmonary 
blood flow may result in damage of the pulmonary endothelium and adhesion and 
migration of polymorphonuclear cells into the lung tissue.  
5.7 Nutrition, Vitamin A 
Premature infants are undernutrition for days and weeks after birth due to critically ill state, 
intolerance of  enteral feeding and fluid restriction. Sick infants have high caloric demand 
for growth, increased work of breathing and metabolism. Inadequate nutrition may amplify 
the lung injury of mechanical ventilation, oxygen toxicity and hinder the repair and 
recovery course. Vitamin C scavenges free oxygen radicals, as well as it interacts with 
vitamine E. Vitamin A is important in regulating early lung development and alveolar 
formation.  Vitamin A deficiency may promote chronic lung disease by impairing lung 
healing, increasing the loss of cilia and squamous-cell metaplasia, increasing susceptibility 
to infection, and decreasing the number of alveoli.  
5.8 Genetics 
Studies in VLBW twins demonstrated that BPD status in one twin was a highly significant 
predictor of BPD in the other twin, irrespective of birth order, Apgar scores and other 
factors. Monozygotic twins had more BPD and a long duration of hospitalization. Lung 
development is regulated by a variety of genes that balance between pro- and anti-
inflammation, oxygen toxicity, cell injury and death, tissue repair, and infection. Specific 
genes that are known to be involved in these biologic pathways have been evaluated for 
their potential contribution to BPD. Approximately half of the initial genetic-association 
studies have not been replicated.  
6. Clinical course 
Most infants who develop BPD usually have various degree of respiratory insufficiency 
resulting from RDS, pneumonia or poor respiratory effort after birth. Oxygen therapy or 
mechanical support is needed to maintain adequate gas exchange. Their pulmonary 
condition may show improvement in the first few days but deteriorate later. The pulmonary 
resistance increases gradually and blood gas shows carbon dioxide retention. Infants require 
more concentrated oxygen and more ventilator support. The deterioration may be triggered 
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by (1)systemic or local infection; (2) the presence of pulmonary edema associated with PDA, 
fluid overload or congestive heart failure; (3) severe airway obstruction caused by 
bronchospasm or tracheobronchomalasia. BPD is often anticipated when mechanical 
ventilation and oxygen supplementation extend beyond10 to 14 days.  
Some infants who have mild or moderate BPD show a slow but steady improvement and 
wean from support after 28 days old. On the other hand, some deteriorate and ultimately 
require months of oxygen supply and ventilator support. Respiratory acidosis with high 
PCO2 greater than 55 mmHg associated with compensated metabolic alkalosis is common. 
Hypoxemia and hypercarbia result from ventilation-perfusion mismatch and alveolar 
hypoventilation.  
The oxygen requirement decrease gradually as the disease process improves, but it can 
increase during feeding, physical activity or episode of infection. Intubated infants are easily 
agitated either because of discomfort or airway obstruction; they are also prone to get 
nosocomial infection. Growth failure with poor weight gain is common due to insufficient 
enteral intake and increase work of breathing. Some infants with severe BPD develop 
pulmonary hypertension, right ventricular hypertrophy and eventually die of right-side 
heart failure (cor pulmonale).  
Radiologic manifestation of mild BPD usually appears normal or mild haziness lung field. 
Moderate to severe BPD may show hyperinflation, lobar or segmental atelectasis, gas 
trapping with pulmonary interstitial emphysema (PIE) and increased lung streaking. 
Fibrosis band and enlarged cyst usually occurs in severe BPD. 
 
Supplemental oxygen and /or ventilator dependent 
Recurrent respiratory infection 
Lung atelectasis 
Gastrointestinal reflux 
Aspiration pneumonia 
Apnea 
Hypertension 
Wheezing and bronchospasm 
Signs of inappropriate ADH 
Signs of pulmonary hypertension and cor-pulmonale 
Poor postnatal growth 
Increase incidence of sudden infant death 
Increase fetal hemoglobin 
                  Neurodevelopmental  delay 
Table 2. Clinical features associated with BPD 
7. Prevention of bronchopulmonary dysplasia 
As stated above, the pathogensis of BPD has been linked to immature lung tissue, 
barotraumas and volutrauma resulting from mechanical ventilation, oxygen injury, and 
proinflammatory factors. Reduction of the incidence and severity of BPD may be possible 
through reduction of the causes of BPD. Among many strategies studied in the past, 
antenatal corticosteroids treatment, postnatal surfactant therapy, and gentle ventilation have 
been proved to be the most effective methods to target the development of BPD and 
decrease its severity.  
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7.1 Pharmacologic agents 
7.1.1 Antenatal corticosteroid 
Antenatal corticosteroid (ANC) was noted to be the most successful agent in reducing 
respiratory syndrome and increasing survival in premature infants by Liggins and Howie in 
1972. It was not widely used until 1994 when the Consensus Development Conference 
Statement of National Institute of Health was published. Now women are at risk of preterm 
birth between 24 and 34 weeks’gestation are routinely given a course of corticosteroid before 
delivery. A single course of antenatal corticosteroids treatment is associated with an overall 
reduction of neonatal death, RDS, intraventricular hemorrhage, necrotizing enteritis, 
respiratory support, intensive care admissions and systemic infections in the first 48hoursof 
life. Long term follow up study demonstrates improvement of neurodevelopmental 
outcomes. Steroids accelerate structural maturation and surfactant synthesis of the lung, 
thus decrease the severity of RDS and BPD. The overall incidence of BPD in the population 
is not decreased due to increased survival of tiny babies. 
Antenatal corticosteroid is most effective if given more than 24 hours after and up to 7 days 
after administration of the second dose of antenatal corticosteroids. Treatment for less than 
24 hours is still associated with better outcome, ANC should be given unless immediately 
delivery is anticipated or there is evidence corticosteroid will have an adverse effect on the 
mother. Caution should be exercised when giving corticosteroid therapy to women with 
systemic infection including tuberculosis and infection. 
Betamethasone is the steroid of choice, when available, to be given in a course of two doses 
of 12mg administered intramuscularly 24 hours apart. An alternative regimen would be four 
doses of 6mg dexamethasone intramuscularly every 12 hours. Betamethasone is associated 
with a greater reduction in the risk of death than dexamethasone; it also decreases risk of 
periventricular leukomalacia which was not found with dexamethasone treatment. Weekly 
repeat course of ANC reduce the occurrence and severity of RDS, but the short benefits are 
upset with a reduction in weight and head circumference. Weekly repeat course of ANC are 
not recommended. Prenatal steroid may decrease airway septation and aveolarization in 
animal, it is not clear if prenatal steroid itself or the associated increased survival of tiny 
infant would contribute to the recently high incidence of new BPD. 
7.1.2 Postnatal surfactant therapy 
The surfactant deficiency lung of premature infants is highly susceptible to lung injury and 
significant inflammatory reaction. The function of surfactant is to recruit alveoli and prevent 
atelectasis. Surfactant replacement reduces initial inspired oxygen and ventilation 
requirements as well as the incidence of respiratory distress syndrome, death, 
pneumothorax, pulmonary interstitial emphysema and the combined outcome of death or 
BPD. Combined use of prenatal steroid and postnatal surfactant therapy has proved to have 
an additive effect in improving lung function. As results of these treatments, the severe 
classic BPD is rarely seen today. 
7.1.3 Methylxanthines 
Apnea of prematurity occurs in at least 85 percent of infants who are less than 34 weeks 
gestation. Widely used treatments include application of continuous positive airway pressure 
and the prescription of methylxanthines. In fact, methylxanthines – caffeine, theophylline and 
aminophylline are one of the most common drugs used in premature infants. They inhibit 
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sleepiness-inducing adenosine and improve respiratory drive, reduce the frequency of apnea 
and the need for mechanical ventilation. Methylxanthines also inhibit TNF-┙ and leukotriene 
synthesis, thereby reducing inflammation and innate immunity.  
Toxicity with theophylline is more common than with caffeine. Side effects are usually 
associated with plasma level over 20ug/ml. Serum levels less than 10ug/ml is not beneficial 
as an aid to wean the ventilator. Because of the narrow range of therapeutic levels of 
theophylline, caffeine is the drug of choice in the treatment of apnea of prematurity. Davis at 
el demonstrated an improvement in minute ventilation, an increase in tidal volume, a 
decrease in lung resistance and improved lung compliance 1 hour following 10 mg/kg of 
caffeine. In a randomized study by Schmidt et al, infant who received caffeine were less 
likely to use oxygen at 36 weeks postmenstrual age, and more likely to have ventilator 
discontinued earlier. 
7.1.4 Postnatal corticosteroid 
Because inflammation plays a central role in the pathogeneses of BPD, systemic corticosteroids 
especial dexamethasone have long been used for prevention and treatment of BPD. Lung 
inflammation is down-regulated by dexamethasone therapy. Dexamethasone is a potent, long 
acting steroid with almost exclusive glucocorticoid effect. Compared to hydrocortisone, 
dexamethasone is 25-50 times more potent. The half-life is 36-54 hours. Dexamethasone has 
been extensively studied in neonatal medicine and has shown to improve pulmonary function, 
facilitate extubation and decrease the incidence of BPD. However; many associated adverse 
side effects prevent the routine use of dexamethasone. The short term side effects include 
hyperglycemia, hypertension, hypertrophic cardiomyopathy, growth failure, GI bleeding and 
perforation. The risk of GI perforation increases with concomitant indomethacin treatment. 
There is also a concern of the chronic suppression of the hypothalamic-pituitary-adrenal axis, 
and long term neurodevelopmental delay. 
Striking evidence from multiple studies of the adverse effects of dexamethasone and its 
long-term neurological effects on preterm infants prompted the American Academy of 
Pediatrics and the Canadian Pediatric Society to strongly discourage the use of 
corticosteroids to prevent or treat BPD in 2002. Since the release of this consensus statement, 
the use of corticosteroids has decreased significant, the incidence and severity of BPD 
increased significantly during this decade. To each gestation age, the time-related increase in 
BPD is inversely related to the decrease of dexamethasone use. The decline in use of 
dexamethasone associated with a concomitant increase in the use hydrocortisone. However, 
the use of hydrocortisone did not have any impact on the rate and severity of BPD. 
7.2 Gentle ventilation 
Mechanical ventilation both causes and treats BPD. When used, lowest ventilator setting to 
obtain adequate ventilation must be applied to minimize the barotrauma-volutrama and 
oxygen toxicity.  
7.2.1 Tidal volume, inspiratory pressure and target range of oxygen saturation 
In premature infants with lung disease, functional residual volume is reduced and some 
parts of alveoli are collapsed. The ideal tidal volume would be that open these collapsed 
area without over-distend the other areas. In general, initial PIP is set 16-20 cmH2O in order 
to achieve a tidal volume of 4-6 ml/Kg in ELBW with respiratory failure. Peak inspiratory 
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pressure >20 mmHg is rarely needed. Peak end expiratory pressure is usually set at 4 
cmH2O, and short inspiratory time 0.3-0.4 seconds are used.  
Oxygen saturation monitored by pulse oximetry offers the most reliable estimate of arterial 
oxygenation and easy to use. The ranges of oxygen saturation should be targeted between 
91 to 95%. Oxygen therapy is very toxic for preterm babies, and maintaining even slightly 
high oxygen saturation contributes to retinopathy of prematurity and increases the duration 
of oxygen treatment. The STOP-ROP (Supplemental Therapeutic Oxygen for prethreshold 
Retinopathy of Prematurity) research group showed that newborn babies who had received 
oxygen supplementation to maintain saturation at 96-99% presented more pneumonia and a 
greater incidence of chronic lung disease than did those whose saturation was maintained at 
89-94%. The results of the Surfactant, Positive Pressure, and Oxygenation Randomized Trial 
(SUPPORT) demonstrated that lower target range of oxygenation at 85to 89% did not 
significantly decrease the combined risk of death or BPD, but it resulted in an increase in 
mortality. 
7.2.2 Permissive hypercarbia 
Higher levels of PCO2 45-65 mmHg with pH above 7.20 now are accepted, thus allowing 
gentle ventilation to minimize lung injury. Early studies suggest that BPD occur more often 
among newborn infants with PaCO2 below 40mmHg. A randomized, controlled study of 
NICH Neonatal network demonstrated that mechanical ventilated extremely low birth 
weight infants who were assigned to minimal ventilation (PCO2 target >52 mm Hg) 
required less ventilator support at 36 weeks compared with infants with routine ventilation 
(PCO2 target <48 mm Hg) (1% vs. 16% respectively, p<0.01). Unfortunately, after enrollment 
of 220 patients, the trial was halted because of unanticipated non-respiratory adverse events 
related to dexamethasone therapy. The relative risk for death or BPD at 36 weeks in both 
groups is no difference. 
7.2.3 Nasal continuous positive pressure (nCPAP) 
Nasal continuous positive pressure supports the breathing through a number of 
mechanisms: (1). splinting the airway thereby preventing airway obstruction, (2). dilating 
the airways and reducing resistance to airflow and so diminishing work of breathing, (3) 
aiding lung expansion and so reducing ventilation perfusion mismatch and improving 
oxygenation. Nasal CPAP used after extubation can prevent the instability associated with 
possible respiratory failure and reintubation.  
Nasal CPAP, rather than intubation and ventilation, might be started shortly after birth for 
infants born at 25 to 28weeks’ gestation. In the randomized, controlled Continuous Positive 
Airway Pressure or Intubtion at Birth (COIN) trial, there were fewer days of ventilation in 
the CPAP group, and a few CPAP infants received oxygen therapy at 28 days, but not at 36 
PMA weeks. The early CPAP group did not significantly reduce the rate of death or BPD. 
Pneumothorax occurs in 6% of the CPAP infants and 3 % in the intubated group. Report 
from SUPPORT study, infants born 24-28 weeks of gestation, were randomly assigned to 
intubation and surfactant treatment, or to CPAP treatment initiated in the delivery room. 
There is no significant difference of death or BPD at 36 weeks. Infants who received CPAP 
treatment, as compared with infants who received intubation and surfactant treatment, less 
frequently required intubation or postnatal corticosteroids for BPD, and required fewer days 
of mechanical ventilation. 
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The value of early CPAP as a replacement of intubation and ventilation apparently to be 
established. Surfactant treatment is most effective if given shortly after birth. Tiny infants 
with respiratory distress receive nCPAP alone after bith may miss the benefit of 
prophylactic surfactant therapy. In our practice, we intubate these infants soon after birth, 
give a dose of surfactant treatment, then extubated and change to CPAP support if infants 
can tolerate, to avoid mechanical ventilation. 
8. Management of BPD 
Despite of the recent advances of neonatal medicine, little progress has been made in 
treatment of BPD. Cornerstones of treatment are pulmonary support to maintain optimal 
oxygen saturation and prevent complications and nutritional support to promote growth. 
Most patients with mild to moderate BPD gradually improve as healing occurs and lung 
growth continues. Infants with severe BPD especial who are ventilator dependent are more 
likely to have acute episodes of pulmonary decompensation secondary due to nosocomial 
infection, severe airway constriction, pulmonary air leak, increased pulmonary edema and 
the development of tracheobronchmalacia or cor pulmonale. Physical examination, 
radiographic survey, laboratory tests and echocardiogram are important in differential 
diagnosis and guide for specific treatment.  
Respiratory support 
Infants with established BPD who are ventilator dependent, gentle ventilation are preferred to 
avoid further lung injury. Oxygen saturation should be kept within 90-95%. Inappropriate low 
oxygen tension may induce pulmonary vasoconstriction and /or bronchospasm with resultant 
increase frequency of apnea and hypoxia. Higher PCO2 (55 to 65 mmHg) is accepted if pH is 
in normal range. Weaning these from mechanical ventilation is difficult and must be 
accomplished gradually. Caffeine or theophylline are usually used during the weaning phase 
to stimulate respiratory drive. Nasal CPAP may be applied to infants after extubation. 
Infants with BPD who are not on oxygen therapy may experience oxygen desaturation with 
feeding or physical activity, additional oxygen supply might be need. 
Phamacologic agents 
Most medications used for treatment of BPD are targeted on one of the following 
pathophysiologic mechanisms of BPD: (1) bronchopulmonary constriction and airway 
hyperreactivity, (2) pulmonary edema, (3) airway inflammation, and (4) chronic lung injury 
and repair. 
Bronchodilators 
Infants with BPD have increased airway resistance due to peribronchial smooth muscle 
hypertrophy and airway hyperactivity. Acute bronchospasm in response to  hypoxia event 
could lead to sudden deteriorating pulmonary status. Bronchodilators have been shown to 
reduce airway resistance, improve lung compliance and increase tidal volume in infants 
with BPD during acute episodes of bronchospasm. However, their effects are usually short-
lived, and many drugs have significant cardiovascular side effects. Inhaled ┚-2 agonists such 
as albuterol or levalbuterol have shown to reverse acute episodes of bronchoconstriction 
and cause few cardiovascular side effects. An initial trial dose can be administered through 
a meter-dose inhaler with a spacer device or as a nebulized solution. If patients show 
improvement of gas exchange, the ┚-2 agonists can be given up to 48hours duration. 
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Chronic use of ┚-2 agonists is not recommended since there is no long term benefit in 
treatment or prevention of BPD in preterm infants. Ipratropium bromide is another 
anticholinergic preparation that dilates airway. 
Methylxanthines are competitive nonselective phosphodiesterase inhibitors, prevent 
breakdown of cyclic AMP and cyclic GMP. This leads to raise intracellular c-AMP and c-
GMP. They also inhibit TNF-┙ and leukotriene synthesis, thereby reducing inflammation 
and innate immunity. Methylxanthines are nonselective adenosine receptor antagonists. 
Adenosine can cause broncho-constriction and potentiate immunologically induced 
mediator release from lung mast cells. Inhibition of this action will cause bronchodilatation. 
Theobromine, a metabolic product of caffeine and theophylline, causes vasodilatation and 
increases urine volume. But methylxanthines are weak bronchodilators with mild diuretic 
effect, and are infrequently used in the treatment for acute bronchospasm.  
Corticosteroid 
As discussed above, systemic corticosteroids improve lung function and reduce the need of 
mechanical ventilation, but because the concern of long term adverse neurological outcome, 
now this treatment is reserved for infants with severe BPD who cannot be weaned from 
ventilator support. Dexamethsone with lower dose and shorter duration are usually used to 
facilitate extubation. A recent pilot study by Yeh et al , has shown that intratracheal 
instillation of budesonide by using surfactant as vehicle can effectively deliver budesonide 
to the lung and suppress the lung inflammation and improves pulmonary outcome without 
significant short term and long term side effects. More studies are needed before it can be 
recommended.  
Nutrition and fluid supply 
Adequate nutrition is difficult to achieve in infants with BPD because of high caloric 
demand, poor tolerance of enteral feeding and restriction of fluid intake. Impaired growth is 
common in these infants. Malnutrion can delay somatic growth and the development of 
new alveoli, making successful weaning from ventilator less likely. Infants with poor 
nutrition are also susceptible to infection. Also, there are special nutrients and vitamins that 
are frequently deficient in these infants and their lack may increase the risk of lung injury. 
Many infants with BPD experience increased energy needs. The reasons for this are not 
entirely clear; increased work of breathing, catecholamine release due to stress, increased 
energy requirements for feeding, and the effects of medications probably all play a role. It is 
not unusual for infants with BPD to require 130 or even 160 Kcal/kg/day to support adequate 
growth. It may be difficult to provide adequate calories for these infants. They may have 
ongoing fluid restrictions due to concerns about pulmonary edema. They may experience 
fatigue with feeding or delayed gastric emptying. Increasing the caloric density of formula or 
breast milk with a balanced proportion of carbohydrate and fat may be helpful. A high 
carbohydrate load increases production of CO2 which may be a concern in infants with 
respiratory compromise. Excess carbohydrate may also lead to osmotic diarrhea. Excess 
dietary fat may delay gastric emptying and exacerbate gastroesopageal reflux. 
Diuretics 
Infants  with  chronic  lung  disease  tend  to retain  interstitial  fluid  which  results  in  
increased  respiratory  distress,  increase  in oxygen  requirement,  increase  in  ventilator 
settings, hypoxemia and hypercarbia. Diuretics mobilize fluid, improve lung compliance 
and decrease resistance. 
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Furosemide 
Furosemide is the most commonly used diuretic. It is a potent and rapid acting loop 
diuretic. It can be used orally and intravenously. The main benefit of the intravenous route 
is a quick response. 
Mechanism of Action: At the ascending loop of Henle, furosemide inhibits active 
reabsorption of chloride resulting in lower sodium and water reabsorption. It also acts 
against antidiuretic hormones, and increases urine aldosterone excretion. Furosemide 
decreases left ventricular filling pressure by increasing venous capacitance. Furosemide 
helps in chronic lung disease by both diuretic and vasculature effects. 
Adverse effects: Main adverse effects of chronic furosemide therapy are hypercalciuria, 
nephrocalcinosis and hypochloremia. Electrolytes should be monitored carefully. 
Ototoxicity is related to plasma concentration and is usually reversible after cessation of 
therapy. Other side effects include: osteopenia, cholelithiasis, displacement of bilirubin and 
hyperparathyroidism. 
According to Cochrane review in preterm infants < 3 weeks of age with BPD, intravenous 
furosemide administration has either inconsistent effects or no detectable effect. In infants 
less than 3 weeks of age with BPD, a single intravenous dose of 1 mg/kg of furosemide 
transiently improves pulmonary mechanics. Chronic enteral or intravenous furosemide 
administration improves both oxygenation and pulmonary mechanics. The Cochrane 
review concluded that there is little evidence to support any benefit of fu- rosemide 
administration with respect to ven- tilatory support, length of hospital stay, survival or 
long-term outcome. Accordingly, routine or sustained uses of systemic loop diuretics in 
infants with BPD cannot be recommended. 
Inhaled furosemide has been shown to transiently improve pulmonary function. No long-
term outcomes have been studied. More trials are needed before this delivery method can be 
recommended for routine use. 
Thiazide Diuretics 
Thiazides work by inhibiting sodium reabsorption in the distal tubule. In contrast to 
furosemide, thiazides decrease calcium excretion. 
Potassium Sparing Diuretic 
Spironolactone is a competitive antagonist of aldosterone. It is a weak diuretic and is usually 
given in combination with thiazides. There are very few randomized control trials. By 
Cochrane reviewer’s opinion, in infants less than 3 weeks of age with BPD, chronic 
administration of thiazide and spironolactone improves lung compliance at four weeks of 
treatment and reduces need for furosemide. Only one study showed long-term benefits such 
as decreased rates of death and artificial ventilation. 
 
Diuretics 
Drug Site of Action Route Onset Dose 
Furosemide Loop diuretic IV PO 15-30 min 
30-60 min 
1 mg/kg/dose 
1-3 mg/kg/dose 
Hydrochlorothiazide Distal tubule PO 1-2 hrs 2-4 mg/kg/day 
Spironolactone Aldosterone 
antagonist 
PO 3-5 days 1.5-3 mg/kg/day 
Table 3. 
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Inhaled Nitric Oxide (INO) 
INO decreases pulmonary vascular resistance and improves oxygenation. It is pro- posed 
that INO will improve oxygenation, improve ventilation and will decrease respiratory 
support. Side effects include methemoglobinemia and direct pulmonary injury if excessive 
INO is used 
Studies on INO were done with different doses, started at different ages, different durations 
of treatment, and in infants whose characteristics were different among the studies. INO 
was approved by FDA to term and near-term infants. AAP Committee on Fetus and 
Newborn recommended that centers that provide INO therapy should provide 
comprehensive long-term medical and neurodevelopment follow-up and should establish 
prospective data collection for treatment time, course, toxic effects, treatment failure, use of 
alternative therapies, and outcomes. 
A systematic review which included 11 studies failed to show a significant benefit of INO on 
BPD. Cochrane database for systematic review by Keith J Barrington in 2006 concluded: INO 
as rescue therapy for the very ill ventilated preterm infant does not appear to be effective, 
and may increase the risk of severe IVH. Later use of INO to prevent BPD also does not 
appear to be effective. Early routine use of INO in mildly sick preterm infants may decrease 
serious brain injury, and may improve survival without BPD. Further studies are needed. 
Antioxidants 
Free radical and oxidant stress cause dam- age to DNA, cell membrane, protein and lipids. 
Free radicals are produced by many mechanisms such as mitochondrial electron transport 
chain, prostaglandin metabolism, ischemia-reperfusion, hypoxia, neutrophil and 
macrophage activations, and endothelial cell hypoxanthine-xanthine oxidation. There is a 
balance between free radical production and clearing by the antioxidant system. The 
antioxidant defense system includes enzymatic components such as Co-Zn superoxide 
dismutase (SOD) glutathione peroxidase, and a non-enzymatic components such as 
glutathione, selenium, zinc, vitamin E and vitamin C. Preterm infants have an immature 
antioxidant defense system, and are highly exposed to oxidant stress, therefore prone to get 
tissue damage. Many antioxidant agents have been tried to treat or prevent BPD in new- 
born. These include: 
Vitamin E: Tocopherol is a fat-soluble, anti- oxidant and it decreases reactive oxygen species 
The American Academy of Pediatrics Committee on Nutrition has recommended daily 
supplementation of 5-25 IU of vitamin E in preterm infants. Supplementing very low birth 
weight infants with vitamin E as an anti- oxidant agent has been proposed for pre- venting 
or limiting retinopathy of prematurity, intracranial hemorrhage, and chronic lung disease. 
In clinical trials, vitamin E supplementation did not affect the incidence of BPD. Vitamin E 
supplementation significantly increased the risk for necrotizing enterocolitis and sepsis. 
Superoxide dismutase: Intra-tracheal ad- ministration of CuZn SOD in preterm infants did 
not reduce BPD. It decreased the need for asthma medications, emergency department visits 
and hospitalizations during the one year follow-up.Rosenfeld et al showed that radiologic 
evidence, clinical signs of BPD and days of CPAP were less in patients treated with SOD, 
and no side effects were observed. Cochrane database concluded that there is insufficient 
evidence that super- oxide dismutase is efficient in preventing chronic lung disease of 
prematurity, but it is well-tolerated, and has no serious adverse effects. 
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N acetyl cysteine (NAC): NAC is a precursor of cysteine, which is essential in Glutathione 
synthesis. Glutathione is a non- enzymatic antioxidant. NAC treatment in preterm infants 
did not prevent BPD or death, and did not improve lung function at discharge from the 
hospital . 
Allopurinol: Allopurinol is inhibitor of xanthine oxidase, an enzyme which generates 
superoxide radicals. It did not decrease BPD in preterm infants of 24-32 weeks' gestation. 
Metaltonin: Metaltonin is a hormone that is found in all biological organisms, and is a 
potent free radical scavenger. Melatonin treatment reduced the proinflammatory cytokines 
(IL-6, IL-8 and tumor necrosis factor (TNF)-alpha), and improved the clinical out- come in 
mechanically ventilated newborns with respiratory distress. 
Vitamin A: Vitamin A is very important for the health of epithelial tissues. It reduces ciliary 
loss, and is associated with increased alveoli. In animals studies, vitamin A deficiency has 
been associated with necrotizing tracheobronchiolitis and squamous metaplasia the changes 
akin to BPD. Very low birth weight infants are known to have low vitamin levels. 
There have been several studies looking at vitamin A in the prevention of BPD. The largest 
study by Tyson et al showed significant decrease (from 62% to 55%) in combined outcome of 
death or chronic lung disease. 
Meta-analysis also revealed similar results. 
A follow-up study did not show any untoward outcome at 18 to 22 months of age. Many 
units routinely use vitamin A for prevention of BPD. Five thousand IU of Vitamin A has to 
be given by tri-weekly intramuscular injections for four weeks. In one study it was given by 
oral route but was not effective in preventing BPD. Intravenous emulsion preparation needs 
to be studied by randomized control trials. 
Cimetidine: In animal studies, lung injury as result of induction of cytochrome P450 by 
oxygen exposure may result in the release of free radical oxidants and arachidonic acid 
metabolites, that can be reduced by cimetidine. In study by Cotton et al of infants weighing 
less than 1250 grams who were mechanically ventilated and required oxygen, Cimetidine 
had no significant effect on the severity of respira tory insufficiency at 10 day postnatal age, 
and did not affect the tracheal aspirate levels of inflammatory markers or arachidonic acid 
metabolites. 
Azithromycin: A macrolid antibiotic, azithromycin, acts act as a free radical scavenger, 
inhibits cytokines, and inhibits neutrophil chemotaxis. In a study by Bal- lard HO et al on 
extremely premature infants requiring mechanical ventilation, azithromycin did not affect 
mortality, incidence of BPD and days on ventilator. 
Alpha-1 protease inhibitor (A1PI): Matrix Metalloproteinase is a member of a family of 
extracellular enzymes that are essential in proteolysis activity against extra cellular matrix 
proteins such as collagen, elastic lamina and fibronectin. These enzymes are produced by 
variety of cells such as fibro- blasts, osteoblasts, macrophages, monocytes and neutrophils. 
These enzymes are essential in growth, tissue remodeling, angiogenesis and wound healing. 
If the balance between activation and inhibition of this enzymes is disturbed, many 
pathological conditions can occur such as bronchopulmonary dysplasia. In a study by 
Stiskal JA et al, the incidence of CLD in survivors was lower in infants treated with 
intravenous A1PI as compared with a placebo group, but the difference was not statistically 
significant. The incidence of pulmonary hemorrhage was lower in the treated group. 
Thyroxine, did not reduce the incidence of BPD. Estradiol and progesterone hormonal 
replacements were studied in 83 infants, but did not show decrease in incidence of BPD. 
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9. Conclusion 
BPD is disease of multi-etiology. A large number of extremely preterm infants who survive 
are developing BPD, but the severity of the lung damage is considerably less than that 
observed in the classic form of BPD. Because most of these infants have only mild initial 
respiratory distress and, therefore, do not receive aggressive ventilation, other factors must 
be involved in the pathogenesis of this new, milder type of BPD. Clinical and 
epidemiological data strongly suggest that infections, either prenatal or postnatal, and the 
presence of PDA are major factors in the development of BPD. For this reason, efforts to 
prevent BPD in extremely low-birth weight infants should include an aggressive approach 
in the prevention and effective treatment of  infections and PDA. BPD has long term adverse 
pulmonary and neurodevelopment outcome. Steroids usage for treatment of BPD also has 
been shown to have adverse neurodevelopment. Available data are sometime conflicting 
and inconclusive; clinicians must use their own clinical judgment to balance the adverse 
effects of BP D with the potential adverse effects of steroids for each individual patient.. 
Very low birth weight  infants who remain on mechanical ventilation after 1 to 2 weeks of 
age are at very high risk of developing BPD . When considering corticosteroid therapy for 
such an infant, clinicians might conclude that the risks of a short course of glucocorticoid 
therapy  is warranted . This individualized decision should be made in conjunction with the 
infant's parents. Other treatment and management are largely been supportive and most of 
them have no long term benefits. A recent pilot study from Yeh et al indicated that  
intratracheal  instillation of budesonide using surfactant as vehicle  can effectively deliver 
budesonide into the lungs and can significantly suppress lung inflammation, improve 
pulmonary outcome and without immediate and long term adverse effect.. More studies are 
needed to prove this. Until that time, proper respiratory care and avoidance of NICU 
infection are the most important steps leading to lower incidence of BPD. 
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